Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relamorelin Extension Study for Diabetic Gastroparesis
NCT03786380Phase 3Terminated
- Sponsor
- Allergan
- Start
- Dec 2018
- Primary completion
- Oct 2020
- Modality
- Peptides, Small Molecules
- Countries
- 30
01
Overview
Phase 3, open-label, single-arm trial of relamorelin in diabetic gastroparesis, sponsored by Allergan. Primary endpoints: Treatment-Emergent Adverse Events at 22 months, Potential Clinically Significant Clinical Laboratory Results at 22 months and 2 more. Started Dec 2018; status: terminated.
02
Drugs
relamorelin
03
Conditions
diabetic gastroparesis
Beyond the preview
Go deeper on NCT03786380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03786380.